866-997-4948(US-Canada Toll Free)

Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market

Published By :

GBI Research

Published Date : Jul 2014

Category :

Therapeutic Area

No. of Pages : N/A

GBI Research, the leading business intelligence provider, has released its latest research: “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market”, which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates. The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019. This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings. The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 – RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) – are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0%

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.

The report includes:

  • A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns
  • Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals
  • A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period
  • Multi-scenario forecasts of the critical care market over the 2013–2020 period in the eight major developed markets
  • Key drivers and restraints that have had and are expected to have a significant impact on the market
  • An overview of major licensing and co-development agreements that could affect growth trends
Reasons to Buy

  • The report will enhance your decision-making capability by allowing you to:
  • Align your product portfolio to markets with high growth potential
  • Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth
  • Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market
  • Develop key strategic initiatives based on an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Albumin in Critical Care
2.1.1 Overview
2.1.2 Diseases or Conditions Indicated for Albumin
2.1.3 Epidemiology
2.1.4 Other Treatment Options
2.1.5 Treatment Patterns
2.2 Anti-Thrombin III Concentrates in Critical Care
2.2.1 Overview
2.2.2 Anti-Thrombin Deficiencies
2.2.3 Epidemiology
2.2.4 Treatment Options
2.2.5 Treatment Patterns
2.3 Factor XIII Concentrates in Critical Care
2.3.1 Overview
2.3.2 FXIII Deficiencies
2.3.3 Epidemiology
2.3.4 Treatment Options
2.3.5 Treatment Patterns
2.4 Fibrinogen Concentrates in Critical Care
2.4.1 Overview
2.4.2 Fibrinogen Deficiencies
2.4.3 Epidemiology
2.4.4 Treatment Options
2.4.5 Treatment Patterns
2.5 Prothrombin Complex Concentrate in Critical Care
2.5.1 Overview
2.5.2 Diseases or Conditions Indicated for Prothrombin Complex Concentrate
2.5.3 Epidemiology
2.5.4 Treatment Options
2.5.5 Treatment Patterns

3 Therapeutic Landscape
3.1 Albumin Products
3.1.1 Buminate (albumin, human) – Baxter
3.1.2 Zenalb (human albumin) – Bio Products Laboratory
3.1.3 Human Albumin Biotest (albumin, human) – Biotest
3.1.4 AlbuRx (albumin) – CSL Behring
3.1.5 Albuminar (albumin, human) 5% – CSL Behring
3.1.6 Albutein (albumin (human)) – Grifols
3.1.7 Albuked (human albumin) – Kedrion
3.1.8 Vialebex (human albumin) – French Fractionation and Biotechnology Laboratory
3.1.9 Albunorm (human albumin) – Octapharma
3.1.10 Alburaas (human albumin) – Shanghai RAAS
3.2 Anti-Thrombin Concentrates
3.2.1 Atryn (antithrombin alfa) – rEVO Biologics
3.2.2 Thrombate III (AT III human) – Grifols
3.2.3 Anbinex (AT III human) – Grifols
3.2.4 Kybernin P (AT III human) – CSL Behring
3.2.5 Aclotine (AT III, human) – French Fractionation and Biotechnology Laboratory
3.2.6 Anti-Thrombin III (AT III human) – Baxter
3.2.7 AT III Kedrion (AT III human) – Kedrion
3.2.8 Neuart (AT III, human) – Mitsubishi Tanabe
3.3 Factor XIII Concentrates
3.3.1 Fibrogammin/Corifact (factor XIII) – CSL Behring
3.3.2 NovoThirteen/Tretten (catridecacog) – Novo Nordisk
3.4 Fibrinogen Concentrates
3.4.1 Haemocomplettan P/Riastap (fibrinogen concentrate, human) – CSL Behring
3.4.2 Clottafact/Clottagen (fibrinogen concentrate, human) – French Fractionation and Biotechnology Laboratory
3.4.3 Other Marketed Fibrinogen Concentrates
3.5 Prothrombin Complex Concentrates
3.5.1 Beriplex P/N/Confidex/Kcentra (Prothrombin Complex Concentrate [Human]) – CSL Behring
3.5.2 Bebulin VH (factor IX complex, vapor heated) – Baxter
3.5.3 Cofact (prothrombin complex concentrate) – Sanquin
3.5.4 Octaplex 500 (human prothrombin complex) – Octapharma
3.5.5 Profilnine SD – Grifols
3.5.6 Uman Complex DI – Kedrion

4 Pipeline for Critical Care Market
4.1 Overview of Pipeline
4.2 Promising Pipeline Candidates
4.2.1 Octaplex 500 (human prothrombin complex) – Octapharma
4.2.2 KW-3357– Kyowa Hakko Kirin
4.2.3 Human AT Concentrate – Grifols

5 Critical Care Market Forecast to 2020
5.1 Geographical Markets
5.1.1 Major Developed Markets
5.1.2 US
5.1.3 Top Five European Countries
5.1.4 Japan
5.1.5 Canada
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers

6 Deals and Strategic Consolidations
6.1 Major Deals
6.1.1 Octapharma Enters Into an Agreement with Pfizer
6.1.2 Grifols to Acquire Blood Transfusion Diagnostics Business from Novartis
6.1.3 Shin Poong Pharmaceutical and French Fractionation and Biotechnology Laboratory form a Korea-based Bio-pharmaceutical Joint Venture
6.1.4 Bain Capital Acquires 80% Stake in Plasma Resources UK
6.1.5 Biomat Acquires Three Plasma Donation Centers from Cangene
6.1.6 BioRx Enters into Co-Marketing Agreement with CSL Behring for Corifact
6.1.7 Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies
6.1.8 Shire Enters into Licensing Agreement with Sangamo BioSciences
6.1.9 Baxter Completes Acquisition of Rights to OBI-1 and Related Assets from Ipsen and Inspiration Biopharma

7 Critical Care Market to 2020 – Appendix
7.1 Abbreviations
7.2 References
7.3 Pipeline Products
7.4 Market Forecasts to 2020
7.4.1 Major Developed Markets
7.4.2 US
7.4.3 UK
7.4.4 France
7.4.5 Germany
7.4.6 Italy
7.4.7 Spain
7.4.8 Japan
7.4.9 Canada
7.5 Research Methodology
7.5.1 Coverage
7.5.2 Secondary Research
7.5.3 Primary Research
7.5.4 Therapeutic Landscape
7.5.5 Geographical Landscape
7.5.6 Pipeline Analysis
7.6 Expert Panel Validation
7.7 Contact Us
7.8 Disclaimer

List of Table

Table 1: Critical Care Market, Atryn, Development Timeline, 2007–2013
Table 2: Critical Care Market, Global, Pharmaceutical Pipeline, 2014
Table 3: Critical Care Market, Major Developed Markets, Market Forecast, 2013–2020
Table 4: Critical Care Market, Major Developed Markets, Albumin, Market Forecast, 2013–2020
Table 5: Critical Care Market, Major Developed Markets, Anti-Thrombin Concentrates, Market Forecast, 2013–2020
Table 6: Critical Care Market, Major Developed Markets, FXIII Concentrates, Market Forecast, 2013–2020
Table 7: Critical Care Market, Major Developed Markets, Fibrinogen Concentrates, Market Forecast, 2013–2020
Table 8: Critical Care Market, Major Developed Markets, Prothrombin Complex Concentrates, Market Forecast, 2013–2020
Table 9: Critical Care Market, US, Market Forecast, 2013–2020
Table 10: Critical Care Market, US, Albumin, Market Forecast, 2013–2020
Table 11: Critical Care Market, US, Anti-Thrombin Concentrates, Market Forecast, 2013–2020
Table 12: Critical Care Market, US, FXIII Concentrates, Market Forecast, 2013–2020
Table 13: Critical Care Market, US, Fibrinogen Concentrates, Market Forecast, 2013–2020
Table 14: Critical Care Market, US, Prothrombin Complex Concentrates, Market Forecast, 2013–2020
Table 15: Critical Care Market, UK, Market Forecast, 2013–2020
Table 16: Critical Care Market, UK, Albumin, Market Forecast, 2013–2020
Table 17: Critical Care Market, UK, Anti-Thrombin Concentrates, Market Forecast, 2013–2020
Table 18: Critical Care Market, UK, FXIII Concentrates, Market Forecast, 2013–2020
Table 19: Critical Care Market, UK, Fibrinogen Concentrates, Market Forecast, 2013–2020
Table 20: Critical Care Market, UK, Market Forecast, Prothrombin Complex Concentrates, 2013–2020
Table 21: Critical Care Market, France, Market Forecast, 2013–2020
Table 22: Critical Care Market, France, Albumin, Market Forecast, 2013–2020
Table 23: Critical Care Market, France, Anti-Thrombin Concentrates, Market Forecast, 2013–2020
Table 24: Critical Care Market, France, FXIII Concentrates, Market Forecast, 2013–2020
Table 25: Critical Care Market, France, Fibrinogen Concentrates, Market Forecast, 2013–2020
Table 26: Critical Care Market, France, Prothrombin Complex Concentrates, Market Forecast, 2013–2020
Table 27: Critical Care Market, Germany, Market Forecast, 2013–2020
Table 28: Critical Care Market, Germany, Albumin, Market Forecast, 2013–2020
Table 29: Critical Care Market, Germany, Anti-Thrombin Concentrates, Market Forecast, 2013–2020
Table 30: Critical Care Market, Germany, FXIII Concentrates, Market Forecast, 2013–2020
Table 31: Critical Care Market, Germany, Fibrinogen Concentrates, Market Forecast, 2013–2020
Table 32: Critical Care Market, Germany, Prothrombin Complex Concentrates, Market Forecast, 2013–2020
Table 33: Critical Care Market, Italy, Market Forecast, 2013–2020
Table 34: Critical Care Market, Italy, Albumin, Market Forecast, 2013–2020
Table 35: Critical Care Market, Italy, Anti-Thrombin Concentrates, Market Forecast, 2013–2020
Table 36: Critical Care Market, Italy, FXIII Concentrates, Market Forecast, 2013–2020
Table 37: Critical Care Market, Italy, Fibrinogen Concentrates, Market Forecast, 2013–2020
Table 38: Critical Care Market, Italy, Prothrombin Complex Concentrates, Market Forecast, 2013–2020
Table 39: Critical Care Market, Spain, Market Forecast, 2013–2020
Table 40: Critical Care Market, Spain, Albumin, Market Forecast, 2013–2020
Table 41: Critical Care Market, Spain, Anti-Thrombin Concentrates, Market Forecast, 2013–2020
Table 42: Critical Care Market, Spain, FXIII Concentrates, Market Forecast, 2013–2020
Table 43: Critical Care Market, Spain, Fibrinogen Concentrates, Market Forecast, 2013–2020
Table 44: Critical Care Market, Spain, Prothrombin Complex Concentrates, Market Forecast, 2013–2020
Table 45: Critical Care Market, Japan, Market Forecast, 2013–2020
Table 46: Critical Care Market, Japan, Albumin, Market Forecast, 2013–2020
Table 47: Critical Care Market, Japan, Anti-Thrombin Concentrates, Market Forecast, 2013–2020
Table 48: Critical Care Market, Japan, FXIII Concentrates, Market Forecast, 2013–2020
Table 49: Critical Care Market, Japan, Fibrinogen Concentrates, Market Forecast, 2013–2020
Table 50: Critical Care Market, Japan, Prothrombin Complex Concentrates, Market Forecast, 2013–2020
Table 51: Critical Care Market, Canada, Market Forecast, 2013–2020
Table 52: Critical Care Market, Canada, Albumin, Market Forecast, 2013–2020
Table 53: Critical Care Market, Canada, Anti-Thrombin Concentrates, Market Forecast, 2013–2020
Table 54: Critical Care Market, Canada, FXIII Concentrates, Market Forecast, 2013–2020
Table 55: Critical Care Market, Canada, Fibrinogen Concentrates, Market Forecast, 2013–2020
Table 56: Critical Care Market, Canada, Prothrombin Complex Concentrates, Market Forecast, 2013–2020

List of Chart

Figure 1: Critical Care Market, Global, Overall Pipeline Analysis (%), 2013
Figure 2: Critical Care Market, Major Developed Markets, Treatment Use Patterns, 2013–2020
Figure 3: Critical Care Market, Major Developed Markets, Revenue ($bn), 2013–2020
Figure 4: Critical Care Market, US, Treatment Use Patterns, 2013–2020
Figure 5: Critical Care Market, US, Annual Cost of Therapy and Revenue, 2013–2020
Figure 6: Critical Care Market, Top Five European Countries, Treatment Use Patterns, 2013 and 2020
Figure 7: Critical Care Market, Top Five European Countries, Annual Cost of Therapy ($), 2013–2020
Figure 8: Critical Care Market, Top Five European Countries, Revenue ($m), 2013–2020
Figure 9: Critical Care Market, Japan, Treatment Use Patterns, 2013–2020
Figure 10: Critical Care Market, Japan, Annual Cost of Therapy and Revenue, 2013–2020
Figure 11: Critical Care Market, Canada, Treatment Use Patterns, 2013–2020
Figure 12: Critical Care Market, Canada, Annual Cost of Therapy and Revenue, 2013–2020
Figure 13: GBI Research Market Forecasting Model

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Vena Cava Filters Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

    Inferior vena cava or posterior vena cava is the largest vein in the human body responsible for carrying de-oxygenated blood from the lower extremities of the body into the right atrium of heart and then to the lungs. Vena cava filter is a medical device designed to prevent blood clots from travelling to lungs. These filters are implanted by interventional radiologists or vascular surgeons and are used as prophylactic aid for pulmonary emboli. ...

  • Cocaine Dependence Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020

    Cocaine is a type of stimulant and appetite suppressant that can be smoked, injected and snorted. Cocaine is extracted from the leaves of the coca plant. In nature, cocaine acts as a triple reuptake inhibitor (TRI) or serotonin–norepinephrine-dopamine reuptake inhibitor, which makes it anesthetic, when taken in low doses. Globally, cocaine dependence is a major public health concern and cause of significant mortality and morbidity. Currentl...

  • Multiple Myeloma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020

    Multiple myeloma is a blood disorder related to leukemia and lymphoma, since it generally arises in bone marrow. In multiple myeloma, certain white blood cells (WBCs) begin to proliferate abnormally within the bone marrow. These cells are known as plasma cells. Plasma cells are responsible for manufacturing antibodies in the body that help fight against any infection. In multiple myeloma, excessive plasma cells release abnormal level of proteins ...